BIOBOHEMIA
This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Policy and Terms of Use.
I accept
Close
Therapeutics pipeline
and development programs
Therapeutics pipeline
and development programs
BioBohemia's strategy is based on development and rapid clinical entry of a cancer vaccine based on SANTAVACTM, a novel universal antigen composition for developing cancer vaccines, demonstration of clinical safety and efficacy of this approach, and follow-on development of additional immunotherapeutic candidates. This strategy will allow for the leveraging of initial development efforts of the most advanced candidate to allow expedient transition for the other candidates.

Biobohemia's therapeutic pipeline includes technologically distinct candidate products, each formulation type having its advantages and disadvantages:
Drug
Pre-IND
Therapeutic SANTAVAC15
dendritic cell vaccine
Preventive SANTAVAC25
dendritic cell vaccine
Therapeutic SANTAVAC15
autologous dendritic
cell vaccine
Therapeutic SANTAVAC15
vaccine
Pre-clinical
Phase 3
Phase 2
Phase 1
In addition to encompassing technologically distinct candidates, the therapeutic pipeline encompasses separate formulations that can also target different types of cancer. Notwithstanding, the development programs are all highly focused on one target: an antigen composition developed by SANTAVACTM technology and intended for development of cancer vaccines against solid tumors. This circumstance simplifies the overall R&D efforts and creates synergy among all of the programs, allowing the programs and their associated achievements to leverage each other.
In addition to encompassing technologically distinct candidates, the therapeutic pipeline encompasses separate formulations that can also target different types of cancer. Notwithstanding, the development programs are all highly focused on one target: an antigen composition developed by SANTAVACTM technology and intended for development of cancer vaccines against solid tumors. This circumstance simplifies the overall R&D efforts and creates synergy among all of the programs, allowing the programs and their associated achievements to leverage each other.